Compare Ally Financial Inc (ALLY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Gilead Sciences, Inc. — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.32B), while Gilead Sciences, Inc. trades at $135.77 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 12.4× Ally Financial Inc's market cap, and Ally Financial Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| ALLY | GILD | |
|---|---|---|
Market Cap | $13.32B | $164.99B |
Sector | Financials | Health |
52-Week High | $47.25 | $155.80 |
52-Week Low | $35.96 | $110.56 |
Dividend Yield | 2.74% | 2.47% |
Enterprise Value | — | $188.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.
Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
